Omadacycline for Community-Acquired Bacterial Pneumonia | Zendy

Roman Stets | Zendy; Monica Popescu | Zendy; Joven Gog | Zendy; Ismail Mitha | Zendy; William Nseir | Zendy; Andrzej Madej | Zendy; Courtney Kirsch | Zendy; Anita Das | Zendy; Lynne Garrity-Ryan | Zendy; Judith N. Steenbergen | Zendy; Amy Manley | Zendy; Paul B. Eckburg | Zendy; Evan Tzanis | Zendy; Paul C. McGovern | Zendy; Evan Loh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Omadacycline for Community-Acquired Bacterial Pneumonia

Author(s) -

Roman Stets,

Monica Popescu,

Joven Gog,

Ismail Mitha,

William Nseir,

Andrzej Madej,

Courtney Kirsch,

Anita Das,

Lynne Garrity-Ryan,

Judith N. Steenbergen,

Amy Manley,

Paul B. Eckburg,

Evan Tzanis,

Paul C. McGovern,

Evan Loh

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1800201

Subject(s) - medicine , pneumonia , bacterial pneumonia , community acquired pneumonia , antibiotics , intensive care medicine , microbiology and biotechnology , biology

Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is active against common pathogens that cause community-acquired bacterial pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research